GGrantIndex
← Leaderboards

Daniel William Cramer

Brigham And Women'S Hospital

Google Scholar ↗PubMed ↗ORCID ↗
$28,464,820
Attributed
$28,464,820
Total exposure
9
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $4.8M · FY2005–22
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22

Funding mix

By agency

NIH$41,750,559 · 10

By mechanism

P50$13,510,527 · 2
R01$12,379,809 · 5
U01$8,988,738 · 1
R35$6,871,485 · 1
M01$0 · 1

Top collaborators

No co-investigators on record.

Most similar at Brigham And Women'S Hospital

Same institution · by research overlap

Others in their field

Top investigators on “Woman”

Research focus

WomanEarly DiagnosisMalignant Neoplasm Of OvarySpecimenCancer RiskMalignant NeoplasmsClinical ResearchBaseEpidemiologyAntibodiesHuman SubjectEventSerumFemaleOvarianBiomarkerAffectAntigensRisk FactorsTissuesDiagnosisData SetEndometriosisImmunity

Grant awards (53)

Mucins and immune cell interactions in ovarian cancer pathogenesis & progression$892,854
R35 · FY2022 · CA · contact PI
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression$916,256
R35 · FY2021 · CA · contact PI
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression$1,029,755
R35 · FY2020 · CA · contact PI
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression$982,295
R35 · FY2019 · CA · contact PI
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression$966,086
R35 · FY2018 · CA · contact PI
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression$1,031,346
R35 · FY2017 · CA · contact PI
Mucins and immune cell interactions in ovarian cancer pathogenesis & progression$1,052,893
R35 · FY2016 · CA · contact PI
Screening and Risk Biomarkers for Ovarian Cancer in EPIC Specimens$428,829
R01 · FY2015 · CA · contact PI
Screening and Risk Biomarkers for Ovarian Cancer in EPIC Specimens$474,155
R01 · FY2014 · CA · contact PI
Screening and Risk Biomarkers for Ovarian Cancer in EPIC Specimens$514,415
R01 · FY2013 · CA · contact PI
Screening and Risk Biomarkers for Ovarian Cancer in EPIC Specimens$566,874
R01 · FY2012 · CA · contact PI
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE$500,000
P50 · FY2010 · CA · contact PI
Partners Southwestern Clinical Epidemiology/Validation$271,800
U01 · FY2010 · CA · contact PI
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE$1,193,174
P50 · FY2009 · CA · contact PI
Partners Southwestern Clinical Epidemiology/Validation$917,404
U01 · FY2009 · CA · contact PI
Risk for New onset of Depression in Perimenopausal Women$356,169
R01 · FY2009 · MH · contact PI
MUC-1 related cancer immunity: determinants and predictive significance$274,214
R01 · FY2009 · CA · contact PI
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE$2,176,201
P50 · FY2008 · CA · contact PI
Partners Southwestern Clinical Epidemiology/Validation$926,029
U01 · FY2008 · CA · contact PI
Risk for New onset of Depression in Perimenopausal Women$504,653
R01 · FY2008 · MH · contact PI
MUC-1 related cancer immunity: determinants and predictive significance$278,781
R01 · FY2008 · CA · contact PI
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE$2,278,757
P50 · FY2007 · CA · contact PI
Partners Southwestern Clinical Epidemiology/Validation$861,745
U01 · FY2007 · CA · contact PI
Genes, Hormones & Environment in an Ovarian Cancer Model$792,972
R01 · FY2007 · CA · contact PI
Risk for New onset of Depression in Perimenopausal Women$500,576
R01 · FY2007 · MH · contact PI
MUC-1 related cancer immunity: determinants and predictive significance$283,348
R01 · FY2007 · CA · contact PI
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE$87,500
P50 · FY2007 · CA · contact PI
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE$2,346,815
P50 · FY2006 · CA · contact PI
Partners Southwestern Clinical Epidemiology/Validation$832,925
U01 · FY2006 · CA · contact PI
Genes, Hormones & Environment in an Ovarian Cancer Model$802,843
R01 · FY2006 · CA · contact PI
MUC-1 related cancer immunity: determinants and predictive significance$291,810
R01 · FY2006 · CA · contact PI
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE$2,403,292
P50 · FY2005 · CA
Genes, Hormones &Environment in an Ovarian Cancer Model$807,171
R01 · FY2005 · CA
Partners Southwestern Clinical Epidemiology/Validation$643,717
U01 · FY2005 · CA
Risk for New onset of Depression in Perimenopausal Women$517,779
R01 · FY2005 · MH
Dana-Farber/Harvard Cancer Center Ovarian Cancer SPORE$2,300,000
P50 · FY2004 · CA
PROTEOMIC/EPIDMIOLOGIC PATHS TO OVARIAN CANCER SCREENING$972,842
U01 · FY2004 · CA
Genes, Hormones &Environment in an Ovarian Cancer Model$757,542
R01 · FY2004 · CA
Administration, Communication, Evaluation, and Planning$224,788
P50 · FY2004 · CA
PROTEOMIC/EPIDMIOLOGIC PATHS TO OVARIAN CANCER SCREENING$971,206
U01 · FY2003 · CA
Genes, Hormones &Environment in an Ovarian Cancer Model$759,307
R01 · FY2003 · CA
PROTEOMIC/EPIDMIOLOGIC PATHS TO OVARIAN CANCER SCREENING$901,265
U01 · FY2002 · CA
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISM$628,739
R01 · FY2002 · CA
EPIDEMIOLOGIC AND BIOLOGIC PREDICTORS OF IVF SUCCESS$331,831
R01 · FY2002 · HD
REPRODUCTIVE HORMONES AND ACETAMINOPHEN STUDY$0
M01 · FY2002 · RR
PROTEOMIC/EPIDMIOLOGIC PATHS TO OVARIAN CANCER SCREENING$921,940
U01 · FY2001 · CA
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISM$683,370
R01 · FY2001 · CA
EPIDEMIOLOGIC AND BIOLOGIC PREDICTORS OF IVF SUCCESS$583,396
R01 · FY2001 · HD
REPRODUCTIVE HORMONES AND ACETAMINOPHEN STUDY$0
M01 · FY2001 · RR
PROTEOMIC/EPIDMIOLOGIC PATHS TO OVARIAN CANCER SCREENING$767,865
U01 · FY2000 · CA
OVARIAN CANCER RISK AND HYPERGONADOTROPIC HYPOGONADISM$671,708
R01 · FY2000 · CA
EPIDEMIOLOGIC AND BIOLOGIC PREDICTORS OF IVF SUCCESS$569,327
R01 · FY2000 · HD
REPRODUCTIVE HORMONES AND ACETAMINOPHEN STUDY$0
M01 · FY2000 · RR